Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 97 clinical trials
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will include continous treatment with Ibrutinib 560 mg day

neutrophil count
growth factor
maintenance treatment
imbruvica
diffuse large b-cell lymphoma
  • 0 views
  • 26 Jan, 2022
  • 1 location
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may

lymphoblasts
monoclonal antibodies
hysterectomy
monoclonal antibody therapy
philadelphia chromosome
  • 2 views
  • 30 Jan, 2022
  • 1 location
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the

vincristine
neutrophil count
measurable disease
b-cell lymphoma
doxorubicin
  • 4 views
  • 28 Jan, 2022
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose

growth factor
erbb2
mammogram
cancer chemotherapy
cancer
  • 36 views
  • 10 Mar, 2021
  • 1 location
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

This is an open-label, single-arm study to evaluate the safety and efficacy of Ibrutinib in subjects with refractory/relapsed autoimmune hemolytic anemia.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

This phase II trial studies how well daratumumab and ibrutinib work in treating patients with chronic lymphocytic leukemia that has come back (relapsed) or has not responded to previous

leukemia
neutrophil count
measurable disease
chronic lymphocytic leukemia
monoclonal antibodies
  • 0 views
  • 14 Apr, 2022
  • 1 location
Obinutuzumab Ibrutinib and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab

neutrophil count
measurable disease
obinutuzumab
venetoclax
lactate dehydrogenase
  • 0 views
  • 11 Mar, 2021
  • 1 location
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL (FIGHT)

This is a phase 2 multicenter national interventional pharmacological study aimed at determining the efficacy of a fixed duration treatment with ibrutinib and obinutuzumab in terms of uMRD in

neutrophil count
obinutuzumab
chronic lymphocytic leukemia
platelet count
progressive disease
  • 0 views
  • 19 Apr, 2022
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

The purpose of the study is to test the efficacy and tolerability of a combination treatment of methotrexate, ibrutinib, and temozolomide (MIT regimen) in treating patients who have newly

neutrophil count
leucovorin
methotrexate
  • 0 views
  • 19 Apr, 2022
  • 2 locations
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune

neutrophil count
malignant brain tumor
MRI
karnofsky performance status
renal function
  • 0 views
  • 23 Apr, 2022
  • 1 location